Kingworld Medicines Gets Exclusive Rights to Two Lingnan Hospital Formulas

Chairman Zhao Lisheng framed the deal as a shift in strategy. "From our traditional role as a sole agent and distributor to proactively sourcing high-quality products at their origin," he said. The products come from years of clinical practice at the hospital, with proven efficacy and established applications, he added.

Zhao also pointed to the manufacturing setup. Morning Gold owns GMP-compliant proprietary Chinese medicine factories in Shenzhen and Hong Kong. Dongguan City Chinese Medicine Hospital runs two national key specialties, four national advantageous specialties in Chinese medicine, and several high-level clinical centers including a China Chest Pain Center and a National Advanced Stroke Center.

Kingworld has spent 30 years building a distribution network that covers 34 provinces and municipalities in China. It represents brands including Nin Jiom Pei Pa Koa, Seirogan and Kingworld Imada Red Flower Oil. The new products slot into that existing channel infrastructure.

The deal is structured as MOUs, not definitive agreements. The next concrete step is the Hong Kong HKC registration for each product, which triggers the production and commercialization timeline. Zhao said the group will use this collaboration as a model to source more hospital-validated products upstream.

For a distributor that has historically acted as a middleman for imported brands, the move represents a push up the value chain – into product origination and exclusive rights to clinical-stage formulas. The risk is execution: regulatory timelines for Chinese medicine registration in Hong Kong and mainland China are not short, and the products still need to clear those hurdles before revenue materializes.